About CanSino Biologics Inc.
CanSino Biologics Inc. is a Chinese biopharmaceutical company founded in 2009 and headquartered in Tianjin, dedicated to the research, development, manufacturing and commercialisation of vaccines for human use. It is listed in Hong Kong and on Shanghai's STAR Market, and presents itself under the motto “Innovation for a safer world”.
The company works across five technology platforms — adenoviral vectors, conjugation, antigen design and recombinant proteins, formulation and mRNA — and counts eight launched products. They include its adenovirus type-5 vectored COVID-19 vaccine, the Menhycia ACYW135 meningococcal conjugate vaccine, the Ad5-EBOV Ebola vaccine developed in China, and diphtheria, tetanus and pertussis products.
Its headquarters and main plant are located in the biomedical park of the TEDA West District in Tianjin. For international partners, CanSino offers a vaccine manufacturer with proprietary platforms, registration experience outside China and a portfolio focused on preventable infectious diseases, all documented on its official English website.
The company works across five technology platforms — adenoviral vectors, conjugation, antigen design and recombinant proteins, formulation and mRNA — and counts eight launched products. They include its adenovirus type-5 vectored COVID-19 vaccine, the Menhycia ACYW135 meningococcal conjugate vaccine, the Ad5-EBOV Ebola vaccine developed in China, and diphtheria, tetanus and pertussis products.
Its headquarters and main plant are located in the biomedical park of the TEDA West District in Tianjin. For international partners, CanSino offers a vaccine manufacturer with proprietary platforms, registration experience outside China and a portfolio focused on preventable infectious diseases, all documented on its official English website.